Arcutis Biotherapeutics, Inc.
ARQT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $2 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $2 | $2 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 21.7% | 23.8% | -7.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 91.2% | 90.8% | 86.6% | 90.3% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 11.2% | -14.7% | -28.3% | -6.2% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 7.5% | -19.5% | -38.1% | -15.1% |
| EPS Diluted | 0.06 | -0.13 | -0.2 | -0.089 |
| % Growth | 146.2% | 35% | -124.2% | – |
| Operating Cash Flow | -$0 | $0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | -$0 | -$0 |